Vigilant Biosciences Announces Distribution Agreements for OncAlert™ Oral Cancer System for Czech Republic and Slovakia, Israel and Baltic Region
FORT LAUDERDALE, Fla., Nov. 17, 2015 /PRNewswire/ -- Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today three exclusive multi-year distribution agreements for sales and marketing of its OncAlertTMOral Cancer System in Czech Republic and Slovakia, Israel and the Baltic Region.
Vigilant Biosciences has previously announced four additional distribution agreements in place throughout Europe, Asia and Australia. The three new agreements further expand Vigilant Biosciences' reach throughout Europe and the Middle East and support the company's goal to deliver accurate and cost-effective tools for clinicians involved in the diagnosis and treatment of oral cancer.
The new distribution partners announced include Dentamed for the distribution of the OncAlert Oral Cancer System to the dental markets in Czech Republic and Slovakia; S.I.R.A.M. Ltd. for distribution of the OncAlert Oral Cancer System to the medical and dental markets in Israel; and the Diamedica OU Group for distribution of the OncAlert Oral Cancer System to the medical and dental markets in the Baltic Region, which includes Estonia, Latvia and Lithuania.
As part of the new multi-year deals the OncAlert Oral Cancer System will be available to customers in these regions starting in the first quarter of 2016.
"We are pleased to announce that we are continuing to expand the distribution channels for the OncAlert Oral Cancer System throughout Europe and the Middle East with these three new agreements," said Matthew H.J. Kim, Founder, Chairman, and CEO of Vigilant Biosciences, Inc. "Through these partnerships, we will be able to provide simple, accurate and cost-effective solutions as an aid in the diagnosis of oral cancer in patients, which will result in earlier detection and intervention."
About the OncAlert Oral Cancer System
Vigilant Biosciences' OncAlert Oral Cancer System includes the OncAlertTM Oral Cancer Rapid Point of Care Test ("OncAlert POC Test") and the OncAlertTM Oral Cancer CD44/Total Protein LAB Test ("OncAlert LAB Assay"). Both products are based on patented technology that detects specific protein markers associated with oral cancer, even prior to the observation of visual or physical symptoms. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The test can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus (HPV-16)). The OncAlert LAB Assay was CE registered in November 2015. The OncAlert Oral Cancer System is not currently available for sale in the United States.
About Oral Cancer
According to the World Health Organization, there are over 600,000 new cases of head and neck cancer and 300,000 deaths each year worldwide. In the United States, more than 54,000 individuals were diagnosed with head and neck cancers in 2014, with 13,500 deaths from the disease. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early diagnosis of oral cancer results in a cure rate of up to 90 percent.
Founded in 1990 and headquartered in Prague with additional offices in the Czech Republic and Slovakia, Dentamed is the leading developer, manufacturer and marketer of high-quality, innovative materials, technology and services for dentists and dental technicians in the Czech Republic and Slovakia. Dentamed is a market leader in the Czech dental market, representing more than 200 suppliers from all over the world and serving about 80 percent of the dentists in Czech republic. Dentamed became part of the Lifco group in 2011.
About S.I.R.A.M. Ltd.
S.I.R.A.M. Ltd. is an Israeli company specializing in the import, marketing and sales of pharmaceuticals, para-pharmaceuticals, medical and dental equipment, and consumer products. Founded in 1984, the Company represents many international suppliers in Israel, selling to hospitals, government institutions, nursing homes, private clinics, and pharmacies. S.I.R.A.M. organizes professional workshops, conducts PR and advertising campaigns, and telemarketing programs.
About Diamedica OU Group
Diamedica began operations in 1991 in Estonia. Latvian and Lithuanian subsidiaries were established in 1993. Today, these companies operate jointly as DIAMEDICA group. The Group specializes mainly in the clinical laboratory diagnostic tools (apparatus, reagents, test kits), and offers its services to the scientific, industrial and environmental laboratories. In addition, it sells hospital equipment (equipment, furniture, supplies). Today Diamedica operates in a range of areas: biochemistry and hematology, immunodiagnostics, microbiology, virology, hospital equipment and supplies.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The company's point-of-care and lab-based tests that comprise its OncAlertTM Oral Cancer System provide noninvasive, accurate, and cost-effective tools designed to enable aiding early detection prior to visible symptoms. The OncAlert LAB Assay was CE registered in November 2015. The OncAlert POC Test is currently undergoing the CE Mark registration process and not yet available for sale in any market at this time. For more information, visit www.vigilantbiosciences.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vigilant-biosciences-announces-distribution-agreements-for-oncalert-oral-cancer-system-for-czech-republic-and-slovakia-israel-and-baltic-region-300179703.html
SOURCE Vigilant Biosciences, Inc.